WO1994003159A1 - Controlled release implants - Google Patents
Controlled release implants Download PDFInfo
- Publication number
- WO1994003159A1 WO1994003159A1 PCT/AU1993/000392 AU9300392W WO9403159A1 WO 1994003159 A1 WO1994003159 A1 WO 1994003159A1 AU 9300392 W AU9300392 W AU 9300392W WO 9403159 A1 WO9403159 A1 WO 9403159A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- coating
- outer coating
- hydrogel
- pulse release
- release implant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
Definitions
- This invention relates to implants containing active ingredients, especially drugs or veterinary products suitable for administration to humans and animals in which the active ingredient is required to be administered in a pulsatile release profile.
- Prior art implants are typically of the reservoir type and usually contain a single active ingredient and provide the continuous release of the active in a zero or first order mode of release kinetics.
- a water insoluble excipient eg, calcium phosphate
- a bioactive agent such as a protein or peptide in an amount sufficient to give the required dosage unit of active ingredient in the final product.
- the bioactive agent is usually in the form of a solution or dispersion or powder to facilitate mixing.
- a water soluble excipient eg, lactose
- if used is then added, together with the other desired additives, eg, a lubricating agent such as magnesium stearate, and mixed to form a homogeneous dry powder.
- the powder is then compressed into a tablet of the desired size and shape.
- the compressed tablet is then coated in a pan coater by spraying with a solution or dispersion of the coating material in an amount sufficient to give implants with the required coating thickness.
- the tablet is coated in a fluidized bed system.
- Melt Processing A sustained release Ivermectin implant for livestock pest control" by T Allan Miller. R O Drummond, D D Oehler in "Controlled Release Delivery Systems” ed. Theodore J Roseman and S Z Mansdorf, 1983,
- Ivermectin in a melt of polyethylene glycol (PEG) (MW 15,000 - 20,000). The solution was then drawn by vacuum into a 3 mm internal diameter Teflon tube and allowed to cool. Upon cooling the resultant solid rod (3mm diameter) was removed and trimmed to the desired weight of 400 mg.
- PEG polyethylene glycol
- Implant products of this type are solid cylindrical rods of varying length and diameter and can have shapes ranging from flat discs to fine needles. This type of implant is useful where a prolonged continuous supply of the drug is required.
- pan coating and Wurster coating methods involve substantial contact between the implants being coated. During the drying process, the coating gets sticky resulting in implants sticking together or "twinning". It has been attempted to overcome this problem by the addition of additives and modifiers in the coating.
- additives and modifiers in the coating.
- the additives which may be used are limited to those substances cleared for regulatory use. Polyester coatings, for example, have been cleared for regulatory use however these present a particular problem in the pan coating method due to adhesion of the particles during the drying process. In addition pinholes and other discontinuities can form in the outer coat during the drying process.
- Vaccination has been used to protect humans and animals against bacterial and viral infectious diseases.
- vaccines prepared in the form of killed suspensions of bacteria or viruses, or in the form of conjugated toxoids repeated injections at specific time intervals are required in order for the vaccination to effect adequate levels of immunological response. These intervals may typically range from a few weeks to several months. Due to prevailing epidemiological, social, economic accessibility, human temperamental, or simply convenience reasons, it is highly desirable that effective protection against diseases can be obtained with single injections.
- the one shot vaccines have to release the actives at the required intervals, i.e. in a pulsatile mode, in the required profile, Le. a "dump".
- a further application of the "one shot vaccine” approach is a 6 month or 12 month contraceptive implant or vaginal suppository which delivers the contraceptive hormones in a succession of pulses, the active ingredient in this application not being a vaccine.
- a further non-vaccine example relates to the need for delivery of reaction mixtures to sites of action, specifically the delivery of the lactoperoxidase thiocyanate enzyme substrate reaction system to the hindguts of piglets in the control of diarrhoea.
- Lactoperoxidase coupled with a peroxide generating oxidase (eg, xanthine and xanthine oxidase) converts SCN to SCNO, a very reactive and lethal ion for microorganisms. Pulse release technology can be used to address the problem of reinfection.
- a controlled release drug delivery device Although the most important attribute of a controlled release drug delivery device is its capability to maintain a therapeutically effective level of drug in an animal body over a scheduled period of time, its adoption ultimately depends on the cost, convenience, and ease of its fabrication and administration (1). In terms of the ease and convenience of administering these devices as implants, shapes like sheets, films or hemispheres are generally impractical. However rods, needles or cylinders are readily adapted for parenteral implantation using a conventional hypodermic needle.
- the pan coating and Wurster coating methods are most amenable to implants of a generally rounded shape.
- the applicant's copending Application PCT/AU93/00083 discloses a method of making implants which are suitable for continuous release of an active ingredient over a period of time which consist of a body member comprising a membrane forming a wall around a core matrix and comprising material which is substantially impervious to the active ingredient contained within the core matrix.
- the cylinder is generally open ended, the active ingredient being released directly through the open ends of the cylinder.
- This separate coating step is expensive, clumsy, and time-consuming.
- one aspect of the present invention contemplates a pulse release implant comprising:
- a first concentric layer comprising dehydrated hydrogel containing an active ingredient
- the biodegradable core may be formed from any suitable material.
- the core is biocompatible.
- the core may be formed from a string, suture or rod.
- hydrogel is used in its ordinary art recognised meaning of a water-based three dimensional nonflowable amorphous structure.
- the gel maybe created by ionic or hydrogen bond interactions.
- Hydrogels of particular interest consist of a solution of a polymer in water which under controllable conditions can be made to adopt either a fluid or semi-solid configuration. This allows the hydrogel to be applied as a fluid to the core member and retain its shape as a semi-solid form.
- Methods to induce the transition include temperature control or the use of cross-linking agents such as calcium ions.
- the temperature control method is suitable for gels such as agar and gelatine and the cross-linking method is suitable for hydrogels formed from substances such as alginate polymers.
- a hydrogel in a fluid form is applied to the axial biodegradable core, a transition to a semi-solid state is induced and the hydrogel is thereby immobilised. In this state, the hydrogel may be cut and otherwise manipulated.
- a dehydrated hydrogel is formed.
- the dehydrated hydrogel forms a rigid solid which is suitable for storage and handling. Any suitable hydrogel may be used. Examples are gelatine, agar, alginates, carrageenan, gum gragacanth, acacia, or corn starch. It may also be desirable to include other components in the first concentric layer.
- the active ingredient is typically a bioactive molecule and includes any native, synthetic or recombinant pharmaceutical agent or food additive or supplement including antigens, antibodies, cytokines, growth promotants, hormones, cancer cell inhibitory molecules or agents, immune stimulants or suppressants, anti-microbial agents including antibiotics, anti-viral agents, vitamins, minerals or inorganic or organic nutrients.
- the active ingredient may comprise one type of bioactive molecule or may be a mixture of different bioactive molecules. In a preferred embodiment the active ingredient includes antigens from the clostridial family.
- the outer coating may be formed of any suitable biocompatible substance.
- the outer coating is generally membranous or polymeric and is substantially impervious to the active ingredient. The majority of the active material will be delivered or released as a result of the removal of the outer coating encasing the first concentric layer.
- suitable coating materials include modified starches, sugars, poly anhydrides, polyorthoesters, bioerodible polyesters and the polylactic/polyglycolic acid family of polymers. Polylactic/polyglycolic acids are particularly suitable as they are widely commercially available with various degradation profiles and have regulatory clearance.
- the coating may have a thickness of from typically 10pm to 1,000pm depending on the application of the implant, and the permeability or degradability of the coating. Sliding
- the implant device may be in any suitable shape including elongate, oval, round, ball, capsule, rod, needle, or cylinder shape. Conveniently, the shape is an elongate cylindrical, rod or needle shape. In a most preferred embodiment, the implant device is elongate and generally cylindrical.
- an axially disposed biodegradable core material is coated with a hydrogel containing an active ingredient to form a concentric coating.
- Smaller discrete gel segments, which remain supported by the biodegradable core can be created by cutting the outer concentric hydrogel layer in such a way that the biodegradable core remains intact and sliding the cut segment along the axially disposed biodegradable core so as to form a space between the discrete gel segments. This operation will hereinafter be referred to as the "cut/slide operation”.
- the cut/slide operation may be performed after the hydrogel has been dried and prior to coating however it is generally easier to perform the cut/slide operation on wet hydrogel. Therefore in the process of the present invention the separation and dehydration steps may take place in either order.
- the hydrogel may be dehydrated before separation into discrete segments although it is preferred that the hydrogel is separated before dehydration.
- the outer coating may be applied in any suitable manner.
- the outer coating may be applied by means of a mould, dipping, spraying or by application via a "rod” or "wick".
- the process of the present invention is readily adaptable for incorporation of heat labile active ingredients. It presents few constraints with respect to the choice of active ingredients; and it should be noted that by using a biodegradable structural support, such as surgical suture, the central core does not need to be removed from the final implant product.
- the present device also provides the basis on which further refinement or sophistication of release can be effected.
- hydrogel layer bioerodible polyorthoester polymers prepared by the reaction between 3,9-bis(ethylidene-2,4,8,10-tetraoxaspiro-[5,5]-undecane) and various ratios of trans-cyclohexanedimethanol and 1,6-hexandiol (2)
- the production method can be readily adopted for mass production of needle injectable implants of antitumour agents such as 5-flurouracil for release in a time independent mode.
- collagen poly (HEMA) hydrogel (1) as the incorporating matrix
- needle injectable implants can be readily mass produced for a variety of hydrophilic or hydrophobic active substance with again a time independent release mode.
- the recipient of the implant may be a human, livestock animal including a ruminant animal, e.g. a sheep, cow, horse, pig, goat or donkey, poultry, e.g. chicken, turkey, goose or game bird, a laboratory test animal, e.g. a rabbit, guinea pig or mouse, companion animal, e.g. dog or cat, or a wild animal in the captive or free state.
- a ruminant animal e.g. a sheep, cow, horse, pig, goat or donkey
- poultry e.g. chicken, turkey, goose or game bird
- laboratory test animal e.g. a rabbit, guinea pig or mouse
- companion animal e.g. dog or cat
- a wild animal in the captive or free state e.g. a wild animal in the captive or free state.
- Administration of the implant may be by any convenient means but is generally by injection via the intravenous, intraperitoneal, intramuscular, sub-cutaneous or intradermal route.
- the device may also be surgically implanted or implanted by subsurgical procedures such as during biopsy procedures. Devices such as these may also be administered by an oral route.
- the amount of active ingredient used in a given implant will vary depending on the type of bioactive molecule, condition in the animal being treated and the presence or absence of agonists to the active ingredient or antagonists to the condition being treated. In general, an effective amount of active ingredient is employed meaning an amount effective to induce, stimulate, promote or otherwise initiate the immediately intended result.
- the effective amount is that required to stimulate an immune response to the antigen.
- the active ingredient will be present in amounts ranging from a few micrograms to gram quantities per implant.
- Figure 1 is a part sectional, part schematic, cross section of an apparatus suitable for preparing implant cores by chemically induced gelling.
- Figure 2 is a part sectional, part schematic, cross section of an apparatus suitable for preparing implant cores by temperature induced gelling.
- Figure 3 is a schematic illustration of spray coating of hydrogel implants.
- Figure 4 is a schematic illustration of rod coating solvent based polymer coating application.
- Figures 5 and 6 are graphs of dye release from 35% (pLa i.v. 1) tolulene rod coated gelatine core implants; in vitro at PBS at pH 7.2, 37 oC.
- FIGS 1 and 2 are part sectional, part schematic, cross sections of the apparatus for preparing implant cores.
- the apparatus consists of a dialysis tube "1" fitted over an upper end portion "2" and a lower end portion "3" and located in sealing engagement by waterproof rubber sealants "4" and "5".
- a supporting line formed of bioerodible core material "6” is maintained under tension by a spring steel bow “7”.
- An inlet port "8” and bleeder hole “9” are provided respectively in the lower and upper end portions "2" and “3”.
- An outer perforated mould “10” is provided to support the dialysis tube “1” and allow the ingress of gelling reagents to the dialysis tube. This outer perforated mould may be hinged to allow easy access to the dialysis tube.
- the dialysis tube "1" is replaced with a teflon tube "11" which may be in two longitudinal halves and the outer perforated mould “10” is replaced with a jacketed temperature control member "12".
- the gel structure is held on the support "6".
- the support "6" is centred using the upper and lower end portions "2" and “3".
- the support line "6" is kept taut using a device "7” made of spring steel resembling a bow. This device serves also as a handle to transport the gel structure for the convenience and security of subsequent gel processing, e.g. drying and coating.
- a central support which forms the bioerodible core "6" e.g. a surgical suture, is positioned at the radial centre in a cylindrical mould "1" or “11" using appropriate positioning guides.
- the inner surface of the mould should be lined with material such as teflon to facilitate cast removal.
- a temperature sensitive implant hydrogel layer or core matrix on the central support may be prepared in the following manner:
- the matrix active ingredient and the hydrogel material in the gelling mix is compounded according to the individual formulations used.
- solutions of hydrogel and active materials are prepared separately and recombined in the proportion prescribed immediately prior to filling into the mould to minimise any possible denaturation or inactivation of the active during the preparation of the hydrogel solution.
- Temperature induced gelling process The assembled mould, the gelling mix and the filling device (eg a syringe) are separately equilibrated to the desired filling temperature. Thermal prefilling equilibration is desirable to prevent blockage during filling and deformities in the gel structure.
- the preparation of the temperature induced gelling solution involves dissolution of a hydrogel, such as gelatine (270 mg), and, if required, an osmotic modifier such as sucrose (750 mg) in water (1.5 ml).
- the stock hydrogel solution is prepared by heating the suspended solutes in a water bath at 100 oC. Subsequent to dissolution, fluidity of the hydrogel solution is best maintained by holding at 37 - 45 °C.
- a stock 'bioactive' solution is prepared by dissolution of the 'active' in water (0.5 ml). This solution is then held on ice.
- the requisite volume of the stock 'bioactive' solution is diluted to the requisite concentration by dissolution with water. This solution is also held on ice.
- the gelling mix may be introduced to the mould by a syringe pump via the inlet "8" while the bleeding hole “9" provides an outflow for air and excess gel solution. Filling is preferably accomplished by one slow continuous action. By filling from bottom upward the process is made essentially trouble free and there is lesser likelihood of deformities in the gel structure due to occluded air bubbles especially in a clean teflon mould. Filling is completed when gelling mix appears to flow from the outlet bleeding hole in the top positioning guide.
- the supporting string is centred by the positioning guides "2" and "3".
- the support line "6" is kept taut using a device "7" within an appropriate dialysis tubing "1” which in turn is enclosed within a rigid perforated support "10" for the convenience of filling and subsequent induction of gelling.
- Ion or chemically induced gelling is best achieved using the perforated mould assembly "10" with filled dialysis tube "1".
- This assembly is filled preferably by one slow continuous action. By filling from bottom upward the process is made essentially trouble free and there is lesser likelihood of deformities in the gel structure due to occluded air bubbles adhering to the dialysis tubing.
- the assembly is then transferred to a container of the inducer solution which may be held at any preferred temperature, for example, at zero degrees Celsius if denaturation of an active is a concern. Equilibration of the inducer across the semi-permeable membrane affords the gelling of the matrix active solution mix.
- 3e Extra time should be allowed to ensure proper gel formation and possible hardening of the gel structure for example, 240 minutes.
- the moulded gel structure referred to above consists of an outer hydrogel layer which is supported by and concentric about an axial support line.
- Smaller discrete gel segments which remain supported by the axial support line can be created by cutting the outer concentric hydrogel layer in such a way that the axial line remains intact and sliding the cut segment along the axial line so as to form a space between the discrete small gel segments.
- the above cut/slide operation may be performed either before or after the concentric hydrogel layer has been dried and prior to coating. However, it is generally easier to perform the cut/slide operation on wet hydrogel.
- the "long section” may be segmented into lengths, e.g. 10 mm, maintained on the support line "6". The supported segments may then be dried and processed as required for specific applications.
- the core matrix may be sectioned subsequent to drying but prior to coating.
- the water based gel structure may be air dried under ambient conditions or at low temperatures (e.g. at 2 °C) by flushing with dry nitrogen gas.
- a gel structure containing about 10% total dry matter takes 8-10 hours to dry the gel to a constant weight at room temperature (21 °C).
- the drying time will be appreciably longer at lower temperatures.
- the drying times are gel composition dependent.
- the gel structure mounted on the support may be reassembled with the 2 halves of the teflon mould of the same internal or different internal diameter to allow for the bioerodible outer coating to be applied to the core.
- the dry cast may be coated with a water impermeable copolymer such as polylactic acid (pLa)/polyglycolic acid (pGa) (85:15) co-polymer to form a coating.
- the dried gel structure on the support "6" may be coated by repeated dipping into a polymeric solution and drying to achieve a thin layer of a substantially water impermeable coating with specific transport characteristics (refer to Example 3).
- the dried gel structure on the support "6" may be coated by repeated spraying with a polymeric solution and drying to achieve a thin layer of a substantially water impermeable coating with specific transport characteristics (refer to Example 4).
- the dried gel structure on the support "6" may be coated by repeated application of a polymeric solution via a "rod” or “wick” and drying to achieve a thin layer of a substantially water impermeable coating with specific transport characteristics (refer to Example 5).
- the release mode of the present device can also be modified by the concentration and composition of the matrix materials.
- the concentration and composition of the matrix materials For example, when agar was used as the matrix material, the release was faster and the extent of release higher. This demonstrates the ability to affect the release rate by changes in matrix composition. Variations include replacement of the water based hydrogel matrix with hydrophobic materials such as glycerol monostearate.
- This example is illustrative of temperature induced gelling and gives evidence of an immunological response to an incorporated antigen.
- the inlets to the moulds were then stoppered and the moulds were allowed to equilibrate at 43 °C for 10-15 minutes before the temperature of the thermal jacket was slowly lowered to that of running cold tap water at about 20 °C over 20 minutes.
- the gel was then solidified by cooling the mould assembly to 0 °C and maintaining it at that temperature for half an hour. After the mixture solidified the moulds were dismantled and the gel structure on a string stretched in a bow was removed carefully in a vertical orientation to avoid horizontal splitting of the gel structure by the stretched support while the gel structure was still fragile.
- the gel structure supported by the string support in a bow were cut and separated in the cut/slide operation and air dried at room temperature overnight (about 18 hours).
- Eudragit E 30D is an aqueous dispersion of poly(meth)acrylic acid esters supplied by Rohm Pharma GmbH Stamm Darmstadt, West Germany. When dry, the gel structures were dismounted from the bow and trimmed to segments of 1 cm length (diameter 3 mm). Each segment was estimated to contain 0.05 ml of the original HSA/human IgG antigen solution.
- Placebo implants were made in exactly the same way as the antigen implants except that the HSA/human IgG solution was replaced by 0.9 ml of 0.1 M NaCl. Evaluation of Implant
- Sheep previously immunised with human serum were implanted subcutaneously on the inside surface of hindlegs using a mechanical implanter fitted with a 2.8 mm internal diameter needle. Two implant segments containing antigen or placebo were given to each sheep.
- results of double immuno diffusion assay showed that there was an increase of antibody titre in recipients of the HSA/human IgG implants but not in those of the placebo.
- the increase in antibody titre was comparable to that obtained when normal immunisation protocol with adjuvanted antigen suspension was used.
- the response in general was maximal at day 9 of the four scheduled sampling days for both the specific anti-IgG and anti-HSA responses.
- immunisation using antigen implants can afford a number of other advantages.
- Immunisation with implants was very simple to perform and compared with the routine method far less time consuming. Apart from the puncture mark caused by the implanter needle, no ulceration or swelling was evident at the implant site. This is in sharp contrast to the situation of routine practices when antigen suspensions, especially those using Freund's adjuvant, are used for immunisation.
- This example is illustrative of chemical induced gelling and is preferred for heat labile active material.
- the ion induced gelling mould was assembled as described above (refer to Figure 1) and equilibrated at room temperature. 7 ml of 3% w/w aqueous sodium alginate [Sigma Co. cat No. A-2033, alginic acid sodium salt medium viscosity, from Macrocystis pyrifera (Kelp)] was mixed thoroughly with 7 ml of Clostridium novyi toxoid at room temperature. The active suspension was a concentrated solution of Clostridium novyi toxoid containing the toxoid produced by the bacteria and 5.3 mg/ml of hydrated aluminium hydroxide added as adjuvant.
- the two suspensions may be held at lower temperatures (eg 4 oC) and mixed at lower temperatures.
- the resultant mixture was transferred with a syringe via the inlet port in the mould assembly to fill the dialysis tube inside to a slight overflow from the outlet bleeder hole with about 7 ml per mould.
- the two mould assemblies were transported into a bath of 500 ml aqueous AlCl 3 solution (0.5% w/w) at room temperature (or if desired at 1 °C) with continuous slow agitation using a magnetic stirrer. Gelling was usually effected within 2-3 hours of immersion but it is our normal practice to leave the gel structures to form for 4 hours.
- the moulds were removed from the gels in a vertical position.
- the resultant gel structures were allowed to dry at room temperature.
- the gels may be surface coated with Eudragit E 30D as previously described and/or reloaded with another layer of toxin alginate gel structure.
- sodium alginate may be directly substituted by K-carrageenan but the temperature during filling of the tube mould needs to be higher to prevent premature gelling of the K-carrageenan.
- the gel inducing agent, AlCl 3 (e.g. 7 ml of 1.5% solution) can be added directly to the 14 ml of the alginate C. novyi mix and the resultant solution mixed thoroughly and quickly.
- EXAMPLE 3 This example illustrates the technique of dip coating of hydrogel implants and provides evidence of pulsatile release in vitro evaluation.
- Polylactic acid (d,l-pLa) of inherent viscosity (i.v.) 1.0 dl/g (supplied by Boehringer Ingelheim) of mass 12 g was dissolved in 120 ml of dichloromethane.
- Phosphate buffered saline (PBS), pH 7.2 was made according to the following recipe:
- hydrogel cores containing red food dye or antigen were manufactured according to the methodology described above using the cut/slide method.
- PBS of volume 10 ml was added to each vial and they were placed in an incubator at 37 °C. Monitoring was carried out using U.V. visible spectroscopy to measure dye release into the solution. One sample commenced dye release early at day 4 and took 14 days to attain 100% release at day 18.
- PBS Phosphate buffered saline
- hydrogel cores containing red food dye or antigen were manufactured according to the methodology described above using the cut/slide method.
- An atomising spray nozzle connected to a compressed air cylinder and to a 250 ml separating funnel which contained the different polymer solutions was used to apply the polymer to the gelatine cores being rotated about the support line using a "rotisserie" mechanism (refer to Figure 3).
- a polymer solution was sprayed onto the implant cores using air brush with a gas pressure of 200 kPa and a distance of 10-30 mm between the air brush outlet to the implant cores.
- the implant core string was hand rotated during spraying in order to obtain uniform coating.
- 65 ml of polymer solution was sprayed on a string of implant cores. Referring to Figure 2, the position on the support line "6" of all implants was noted, seven of those were selected at random and their weights recorded.
- a method of coating gelatine cores was investigated to try to overcome the difficulty of covering the ends and edges of the core when spray coating.
- a saturated viscous solution of polylactic acid (d,l-pLa) of inherent viscosity (i.v.) 1.0 dl/g in dichloromethane (20% w/v) was made.
- d,l-pLa polylactic acid
- i.v. inherent viscosity
- a connected series of gelatine cores supported on an axial support was made using the cut/slide operation as described above. It was found that if one large viscous drop of material was spread along a slowly rotating gelatine core (approximately 120 rpm), the drop remained evenly dispersed and seemed to successfully surround the sharp edges and the end of the core (Fig. 4A).
- This example shows the use of implants to obtain pulsatile release in animals.
- An experiment was performed in which the delayed release from implants of tetanus toxoid was demonstrated by detecting by ELISA antibodies produced by the mice in response to the released antigen.
- Implants were made as described in Example 4 except that 0.5 mg tetanus toxoid per implant was used as the active ingredient.
- Antigens were used in implants with two coat compositions and the control group (3) received antigen in uncoated gelatine cores. Mice were implanted subcutaneously on the inside surface of hind legs using a mechanical implanter fitted with a 2.8 mm internal diameter needle. One implant segment containing antigen or placebo was given to each mouse.
- ABTS 2,2'-azino-bis(s-ethylbenzthiazoline-6-sulphonic acid)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93915569A EP0652745A1 (en) | 1992-07-31 | 1993-08-02 | Controlled release implants |
AU45523/93A AU4552393A (en) | 1992-07-31 | 1993-08-02 | Controlled release implants |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPL3879 | 1992-07-31 | ||
AUPL387992 | 1992-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994003159A1 true WO1994003159A1 (en) | 1994-02-17 |
Family
ID=3776329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1993/000392 WO1994003159A1 (en) | 1992-07-31 | 1993-08-02 | Controlled release implants |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0652745A1 (en) |
CA (1) | CA2141459A1 (en) |
WO (1) | WO1994003159A1 (en) |
ZA (1) | ZA935569B (en) |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0788340A1 (en) * | 1994-10-25 | 1997-08-13 | Daratech Pty. Ltd. | Controlled release container with core and outer shell |
US6319512B1 (en) * | 1997-06-04 | 2001-11-20 | Debio Recherche Pharmaceutique Sa | Implants for controlled release of pharmaceutically active principles and method for making same |
US6998134B2 (en) | 1998-09-11 | 2006-02-14 | Gerhard Schmidmaier | Biologically active implants |
US8388546B2 (en) | 2006-10-23 | 2013-03-05 | Bard Access Systems, Inc. | Method of locating the tip of a central venous catheter |
US8437833B2 (en) | 2008-10-07 | 2013-05-07 | Bard Access Systems, Inc. | Percutaneous magnetic gastrostomy |
US8478382B2 (en) | 2008-02-11 | 2013-07-02 | C. R. Bard, Inc. | Systems and methods for positioning a catheter |
US8512256B2 (en) | 2006-10-23 | 2013-08-20 | Bard Access Systems, Inc. | Method of locating the tip of a central venous catheter |
USD699359S1 (en) | 2011-08-09 | 2014-02-11 | C. R. Bard, Inc. | Ultrasound probe head |
US8781555B2 (en) | 2007-11-26 | 2014-07-15 | C. R. Bard, Inc. | System for placement of a catheter including a signal-generating stylet |
US8801693B2 (en) | 2010-10-29 | 2014-08-12 | C. R. Bard, Inc. | Bioimpedance-assisted placement of a medical device |
USD724745S1 (en) | 2011-08-09 | 2015-03-17 | C. R. Bard, Inc. | Cap for an ultrasound probe |
US9125578B2 (en) | 2009-06-12 | 2015-09-08 | Bard Access Systems, Inc. | Apparatus and method for catheter navigation and tip location |
US9211107B2 (en) | 2011-11-07 | 2015-12-15 | C. R. Bard, Inc. | Ruggedized ultrasound hydrogel insert |
US9339206B2 (en) | 2009-06-12 | 2016-05-17 | Bard Access Systems, Inc. | Adaptor for endovascular electrocardiography |
US9445734B2 (en) | 2009-06-12 | 2016-09-20 | Bard Access Systems, Inc. | Devices and methods for endovascular electrography |
US9456766B2 (en) | 2007-11-26 | 2016-10-04 | C. R. Bard, Inc. | Apparatus for use with needle insertion guidance system |
US9492097B2 (en) | 2007-11-26 | 2016-11-15 | C. R. Bard, Inc. | Needle length determination and calibration for insertion guidance system |
US9521961B2 (en) | 2007-11-26 | 2016-12-20 | C. R. Bard, Inc. | Systems and methods for guiding a medical instrument |
US9532724B2 (en) | 2009-06-12 | 2017-01-03 | Bard Access Systems, Inc. | Apparatus and method for catheter navigation using endovascular energy mapping |
US9549685B2 (en) | 2007-11-26 | 2017-01-24 | C. R. Bard, Inc. | Apparatus and display methods relating to intravascular placement of a catheter |
US9554716B2 (en) | 2007-11-26 | 2017-01-31 | C. R. Bard, Inc. | Insertion guidance system for needles and medical components |
US20170065749A1 (en) * | 2014-02-19 | 2017-03-09 | Cousin Biotech | Implantable device, especially for the reconstruction of the abdominal wall |
US9636031B2 (en) | 2007-11-26 | 2017-05-02 | C.R. Bard, Inc. | Stylets for use with apparatus for intravascular placement of a catheter |
US9681823B2 (en) | 2007-11-26 | 2017-06-20 | C. R. Bard, Inc. | Integrated system for intravascular placement of a catheter |
US9839372B2 (en) | 2014-02-06 | 2017-12-12 | C. R. Bard, Inc. | Systems and methods for guidance and placement of an intravascular device |
US10004875B2 (en) | 2005-08-24 | 2018-06-26 | C. R. Bard, Inc. | Stylet apparatuses and methods of manufacture |
US10046139B2 (en) | 2010-08-20 | 2018-08-14 | C. R. Bard, Inc. | Reconfirmation of ECG-assisted catheter tip placement |
US10349890B2 (en) | 2015-06-26 | 2019-07-16 | C. R. Bard, Inc. | Connector interface for ECG-based catheter positioning system |
US10449330B2 (en) | 2007-11-26 | 2019-10-22 | C. R. Bard, Inc. | Magnetic element-equipped needle assemblies |
US10524691B2 (en) | 2007-11-26 | 2020-01-07 | C. R. Bard, Inc. | Needle assembly including an aligned magnetic element |
US10639008B2 (en) | 2009-10-08 | 2020-05-05 | C. R. Bard, Inc. | Support and cover structures for an ultrasound probe head |
US10751509B2 (en) | 2007-11-26 | 2020-08-25 | C. R. Bard, Inc. | Iconic representations for guidance of an indwelling medical device |
US10774137B2 (en) | 2017-01-24 | 2020-09-15 | Société des Produits Nestlé S.A. | Compositions and methods for reducing at least one symptom of human allergy to cats |
US10820885B2 (en) | 2012-06-15 | 2020-11-03 | C. R. Bard, Inc. | Apparatus and methods for detection of a removable cap on an ultrasound probe |
US10849695B2 (en) | 2007-11-26 | 2020-12-01 | C. R. Bard, Inc. | Systems and methods for breaching a sterile field for intravascular placement of a catheter |
US10973584B2 (en) | 2015-01-19 | 2021-04-13 | Bard Access Systems, Inc. | Device and method for vascular access |
US10992079B2 (en) | 2018-10-16 | 2021-04-27 | Bard Access Systems, Inc. | Safety-equipped connection systems and methods thereof for establishing electrical connections |
US11000207B2 (en) | 2016-01-29 | 2021-05-11 | C. R. Bard, Inc. | Multiple coil system for tracking a medical device |
US11027101B2 (en) | 2008-08-22 | 2021-06-08 | C. R. Bard, Inc. | Catheter assembly including ECG sensor and magnetic assemblies |
US11103213B2 (en) | 2009-10-08 | 2021-08-31 | C. R. Bard, Inc. | Spacers for use with an ultrasound probe |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4434153A (en) * | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
JPS62120315A (en) * | 1985-11-20 | 1987-06-01 | Shin Etsu Chem Co Ltd | Production of sustained release tablet |
GB2189995A (en) * | 1986-05-09 | 1987-11-11 | Alza Corp | Dosage dispenser containing osmotic solute and hydrogel |
AU7183787A (en) * | 1986-05-09 | 1987-11-12 | Alza Corporation | Pulsed drug delivery |
AU4787790A (en) * | 1989-01-12 | 1990-07-19 | Pfizer Inc. | Dispensing devices powered by hydrogel |
US4961932A (en) * | 1987-10-26 | 1990-10-09 | Alza Corporation | Plurality of tiny pills in liquid dosage form |
EP0250374B1 (en) * | 1986-06-17 | 1991-05-02 | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. | Therapeutic system for controlled release of drugs |
AU2107392A (en) * | 1991-09-11 | 1993-03-18 | Euro-Celtique S.A. | Controlled release matrix for pharmaceuticals |
WO1993017662A1 (en) * | 1992-03-02 | 1993-09-16 | Daratech Pty. Ltd. | Improved implants |
-
1993
- 1993-08-02 EP EP93915569A patent/EP0652745A1/en not_active Withdrawn
- 1993-08-02 ZA ZA935569A patent/ZA935569B/en unknown
- 1993-08-02 WO PCT/AU1993/000392 patent/WO1994003159A1/en not_active Application Discontinuation
- 1993-08-02 CA CA002141459A patent/CA2141459A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4434153A (en) * | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
JPS62120315A (en) * | 1985-11-20 | 1987-06-01 | Shin Etsu Chem Co Ltd | Production of sustained release tablet |
GB2189995A (en) * | 1986-05-09 | 1987-11-11 | Alza Corp | Dosage dispenser containing osmotic solute and hydrogel |
AU7183787A (en) * | 1986-05-09 | 1987-11-12 | Alza Corporation | Pulsed drug delivery |
EP0250374B1 (en) * | 1986-06-17 | 1991-05-02 | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. | Therapeutic system for controlled release of drugs |
US4961932A (en) * | 1987-10-26 | 1990-10-09 | Alza Corporation | Plurality of tiny pills in liquid dosage form |
AU4787790A (en) * | 1989-01-12 | 1990-07-19 | Pfizer Inc. | Dispensing devices powered by hydrogel |
AU2107392A (en) * | 1991-09-11 | 1993-03-18 | Euro-Celtique S.A. | Controlled release matrix for pharmaceuticals |
WO1993017662A1 (en) * | 1992-03-02 | 1993-09-16 | Daratech Pty. Ltd. | Improved implants |
Non-Patent Citations (2)
Title |
---|
DERWENT JAPIO Online Accession No. 87-120315; & JP,A,62 120 315 (SHIN ETSU CHEM CO LTD) 1 June 1987 (01.06.87), see Abstract. * |
DERWENT WPAT Online Accession No. 93-303101; & WO,A,9317662 (DARATECH PTY LTD) 16 September 1993 (16.09.93), see Abstract. * |
Cited By (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0788340A1 (en) * | 1994-10-25 | 1997-08-13 | Daratech Pty. Ltd. | Controlled release container with core and outer shell |
EP0788340A4 (en) * | 1994-10-25 | 1998-11-04 | Daratech Pty Ltd | Controlled release container with core and outer shell |
US6319512B1 (en) * | 1997-06-04 | 2001-11-20 | Debio Recherche Pharmaceutique Sa | Implants for controlled release of pharmaceutically active principles and method for making same |
US10646622B2 (en) | 1998-09-11 | 2020-05-12 | Gerhard Schmidmaier | Biologically active implants |
US6998134B2 (en) | 1998-09-11 | 2006-02-14 | Gerhard Schmidmaier | Biologically active implants |
US10004875B2 (en) | 2005-08-24 | 2018-06-26 | C. R. Bard, Inc. | Stylet apparatuses and methods of manufacture |
US11207496B2 (en) | 2005-08-24 | 2021-12-28 | C. R. Bard, Inc. | Stylet apparatuses and methods of manufacture |
US8388546B2 (en) | 2006-10-23 | 2013-03-05 | Bard Access Systems, Inc. | Method of locating the tip of a central venous catheter |
US8512256B2 (en) | 2006-10-23 | 2013-08-20 | Bard Access Systems, Inc. | Method of locating the tip of a central venous catheter |
US9833169B2 (en) | 2006-10-23 | 2017-12-05 | Bard Access Systems, Inc. | Method of locating the tip of a central venous catheter |
US8774907B2 (en) | 2006-10-23 | 2014-07-08 | Bard Access Systems, Inc. | Method of locating the tip of a central venous catheter |
US9345422B2 (en) | 2006-10-23 | 2016-05-24 | Bard Acess Systems, Inc. | Method of locating the tip of a central venous catheter |
US8858455B2 (en) | 2006-10-23 | 2014-10-14 | Bard Access Systems, Inc. | Method of locating the tip of a central venous catheter |
US9265443B2 (en) | 2006-10-23 | 2016-02-23 | Bard Access Systems, Inc. | Method of locating the tip of a central venous catheter |
US11707205B2 (en) | 2007-11-26 | 2023-07-25 | C. R. Bard, Inc. | Integrated system for intravascular placement of a catheter |
US9554716B2 (en) | 2007-11-26 | 2017-01-31 | C. R. Bard, Inc. | Insertion guidance system for needles and medical components |
US11134915B2 (en) | 2007-11-26 | 2021-10-05 | C. R. Bard, Inc. | System for placement of a catheter including a signal-generating stylet |
US10449330B2 (en) | 2007-11-26 | 2019-10-22 | C. R. Bard, Inc. | Magnetic element-equipped needle assemblies |
US11123099B2 (en) | 2007-11-26 | 2021-09-21 | C. R. Bard, Inc. | Apparatus for use with needle insertion guidance system |
US10342575B2 (en) | 2007-11-26 | 2019-07-09 | C. R. Bard, Inc. | Apparatus for use with needle insertion guidance system |
US8781555B2 (en) | 2007-11-26 | 2014-07-15 | C. R. Bard, Inc. | System for placement of a catheter including a signal-generating stylet |
US10238418B2 (en) | 2007-11-26 | 2019-03-26 | C. R. Bard, Inc. | Apparatus for use with needle insertion guidance system |
US10966630B2 (en) | 2007-11-26 | 2021-04-06 | C. R. Bard, Inc. | Integrated system for intravascular placement of a catheter |
US9456766B2 (en) | 2007-11-26 | 2016-10-04 | C. R. Bard, Inc. | Apparatus for use with needle insertion guidance system |
US9492097B2 (en) | 2007-11-26 | 2016-11-15 | C. R. Bard, Inc. | Needle length determination and calibration for insertion guidance system |
US9521961B2 (en) | 2007-11-26 | 2016-12-20 | C. R. Bard, Inc. | Systems and methods for guiding a medical instrument |
US9526440B2 (en) | 2007-11-26 | 2016-12-27 | C.R. Bard, Inc. | System for placement of a catheter including a signal-generating stylet |
US10849695B2 (en) | 2007-11-26 | 2020-12-01 | C. R. Bard, Inc. | Systems and methods for breaching a sterile field for intravascular placement of a catheter |
US9549685B2 (en) | 2007-11-26 | 2017-01-24 | C. R. Bard, Inc. | Apparatus and display methods relating to intravascular placement of a catheter |
US11529070B2 (en) | 2007-11-26 | 2022-12-20 | C. R. Bard, Inc. | System and methods for guiding a medical instrument |
US10751509B2 (en) | 2007-11-26 | 2020-08-25 | C. R. Bard, Inc. | Iconic representations for guidance of an indwelling medical device |
US9636031B2 (en) | 2007-11-26 | 2017-05-02 | C.R. Bard, Inc. | Stylets for use with apparatus for intravascular placement of a catheter |
US9681823B2 (en) | 2007-11-26 | 2017-06-20 | C. R. Bard, Inc. | Integrated system for intravascular placement of a catheter |
US11779240B2 (en) | 2007-11-26 | 2023-10-10 | C. R. Bard, Inc. | Systems and methods for breaching a sterile field for intravascular placement of a catheter |
US10524691B2 (en) | 2007-11-26 | 2020-01-07 | C. R. Bard, Inc. | Needle assembly including an aligned magnetic element |
US10231753B2 (en) | 2007-11-26 | 2019-03-19 | C. R. Bard, Inc. | Insertion guidance system for needles and medical components |
US9999371B2 (en) | 2007-11-26 | 2018-06-19 | C. R. Bard, Inc. | Integrated system for intravascular placement of a catheter |
US10165962B2 (en) | 2007-11-26 | 2019-01-01 | C. R. Bard, Inc. | Integrated systems for intravascular placement of a catheter |
US10602958B2 (en) | 2007-11-26 | 2020-03-31 | C. R. Bard, Inc. | Systems and methods for guiding a medical instrument |
US10105121B2 (en) | 2007-11-26 | 2018-10-23 | C. R. Bard, Inc. | System for placement of a catheter including a signal-generating stylet |
US8478382B2 (en) | 2008-02-11 | 2013-07-02 | C. R. Bard, Inc. | Systems and methods for positioning a catheter |
US8971994B2 (en) | 2008-02-11 | 2015-03-03 | C. R. Bard, Inc. | Systems and methods for positioning a catheter |
US11027101B2 (en) | 2008-08-22 | 2021-06-08 | C. R. Bard, Inc. | Catheter assembly including ECG sensor and magnetic assemblies |
US8437833B2 (en) | 2008-10-07 | 2013-05-07 | Bard Access Systems, Inc. | Percutaneous magnetic gastrostomy |
US9907513B2 (en) | 2008-10-07 | 2018-03-06 | Bard Access Systems, Inc. | Percutaneous magnetic gastrostomy |
US9339206B2 (en) | 2009-06-12 | 2016-05-17 | Bard Access Systems, Inc. | Adaptor for endovascular electrocardiography |
US10912488B2 (en) | 2009-06-12 | 2021-02-09 | Bard Access Systems, Inc. | Apparatus and method for catheter navigation and tip location |
US10271762B2 (en) | 2009-06-12 | 2019-04-30 | Bard Access Systems, Inc. | Apparatus and method for catheter navigation using endovascular energy mapping |
US10231643B2 (en) | 2009-06-12 | 2019-03-19 | Bard Access Systems, Inc. | Apparatus and method for catheter navigation and tip location |
US9125578B2 (en) | 2009-06-12 | 2015-09-08 | Bard Access Systems, Inc. | Apparatus and method for catheter navigation and tip location |
US11419517B2 (en) | 2009-06-12 | 2022-08-23 | Bard Access Systems, Inc. | Apparatus and method for catheter navigation using endovascular energy mapping |
US9532724B2 (en) | 2009-06-12 | 2017-01-03 | Bard Access Systems, Inc. | Apparatus and method for catheter navigation using endovascular energy mapping |
US9445734B2 (en) | 2009-06-12 | 2016-09-20 | Bard Access Systems, Inc. | Devices and methods for endovascular electrography |
US11103213B2 (en) | 2009-10-08 | 2021-08-31 | C. R. Bard, Inc. | Spacers for use with an ultrasound probe |
US10639008B2 (en) | 2009-10-08 | 2020-05-05 | C. R. Bard, Inc. | Support and cover structures for an ultrasound probe head |
US10046139B2 (en) | 2010-08-20 | 2018-08-14 | C. R. Bard, Inc. | Reconfirmation of ECG-assisted catheter tip placement |
US9415188B2 (en) | 2010-10-29 | 2016-08-16 | C. R. Bard, Inc. | Bioimpedance-assisted placement of a medical device |
US8801693B2 (en) | 2010-10-29 | 2014-08-12 | C. R. Bard, Inc. | Bioimpedance-assisted placement of a medical device |
USD699359S1 (en) | 2011-08-09 | 2014-02-11 | C. R. Bard, Inc. | Ultrasound probe head |
USD724745S1 (en) | 2011-08-09 | 2015-03-17 | C. R. Bard, Inc. | Cap for an ultrasound probe |
USD754357S1 (en) | 2011-08-09 | 2016-04-19 | C. R. Bard, Inc. | Ultrasound probe head |
US9211107B2 (en) | 2011-11-07 | 2015-12-15 | C. R. Bard, Inc. | Ruggedized ultrasound hydrogel insert |
US10820885B2 (en) | 2012-06-15 | 2020-11-03 | C. R. Bard, Inc. | Apparatus and methods for detection of a removable cap on an ultrasound probe |
US10863920B2 (en) | 2014-02-06 | 2020-12-15 | C. R. Bard, Inc. | Systems and methods for guidance and placement of an intravascular device |
US9839372B2 (en) | 2014-02-06 | 2017-12-12 | C. R. Bard, Inc. | Systems and methods for guidance and placement of an intravascular device |
US20170065749A1 (en) * | 2014-02-19 | 2017-03-09 | Cousin Biotech | Implantable device, especially for the reconstruction of the abdominal wall |
US10632233B2 (en) * | 2014-02-19 | 2020-04-28 | Cousin Biotech | Implantable device, especially for the reconstruction of the abdominal wall |
US10973584B2 (en) | 2015-01-19 | 2021-04-13 | Bard Access Systems, Inc. | Device and method for vascular access |
US11026630B2 (en) | 2015-06-26 | 2021-06-08 | C. R. Bard, Inc. | Connector interface for ECG-based catheter positioning system |
US10349890B2 (en) | 2015-06-26 | 2019-07-16 | C. R. Bard, Inc. | Connector interface for ECG-based catheter positioning system |
US11000207B2 (en) | 2016-01-29 | 2021-05-11 | C. R. Bard, Inc. | Multiple coil system for tracking a medical device |
US10774137B2 (en) | 2017-01-24 | 2020-09-15 | Société des Produits Nestlé S.A. | Compositions and methods for reducing at least one symptom of human allergy to cats |
US11649278B2 (en) | 2017-01-24 | 2023-05-16 | Société des Produits Nestlé S.A. | Compositions and methods for reducing at least one symptom of human allergy to cats |
US10992079B2 (en) | 2018-10-16 | 2021-04-27 | Bard Access Systems, Inc. | Safety-equipped connection systems and methods thereof for establishing electrical connections |
US11621518B2 (en) | 2018-10-16 | 2023-04-04 | Bard Access Systems, Inc. | Safety-equipped connection systems and methods thereof for establishing electrical connections |
Also Published As
Publication number | Publication date |
---|---|
ZA935569B (en) | 1994-04-12 |
CA2141459A1 (en) | 1994-02-17 |
EP0652745A1 (en) | 1995-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994003159A1 (en) | Controlled release implants | |
KR940000001B1 (en) | Process for preparing controlled release delivery system | |
US6682754B2 (en) | Ovo delivery of an immunogen containing implant | |
US5916584A (en) | Controlled release container with core and outer shell | |
Shakweh et al. | Particle uptake by Peyer’s patches: a pathway for drug and vaccine delivery | |
US4919929A (en) | Mammal immunization | |
JP3524096B2 (en) | Use of an acyl exchange reaction between an esterified polysaccharide and a polyamine to form a film on at least the surface of the gelled particles in an aqueous medium, particles formed thereby, methods for their preparation and compositions containing said particles | |
US5368861A (en) | Gastric preparation with sustained release | |
JPH06507412A (en) | Implantable and biocompatible immunoblocking vehicles for the release of selected therapeutic substances | |
NO326966B1 (en) | Particle preparation for therapeutic use, suitable for administration by inhalation, pulmonary delivery device for a therapeutic agent, and method for preparing the particles | |
Polk et al. | Oral delivery in aquaculture: controlled release of proteins from chitosan-alginate microcapsules | |
EP0462959A1 (en) | Coated veterinary implants. | |
JPS6244919B2 (en) | ||
JPH09505995A (en) | Method of introducing substances into eggs in early embryogenesis | |
US5871751A (en) | Renibacterium salmoninarum vaccine and method for its preparation | |
JPH09505994A (en) | Method and device for in ovo injection of early embryos | |
WO1994007469A1 (en) | An immunobooster for delayed release of immunogen | |
AU701890B2 (en) | Gel form of a vaccine | |
RU2313366C2 (en) | Composition and method for controlled releasing of injection solutions | |
EP0300102B1 (en) | Improved method of obtaining immune regulatory factors by mammal immunization | |
AU4552393A (en) | Controlled release implants | |
WO1993017662A1 (en) | Improved implants | |
US20020041925A1 (en) | Apparatus and method for coating a material | |
RU2326655C1 (en) | Method of incapsulation of protein bearing materials in microspheres from copolymer polylactide-polyglycolide | |
HUT72986A (en) | Microporous macrocapsules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 254017 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993915569 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1995 379456 Country of ref document: US Date of ref document: 19950127 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2141459 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1993915569 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993915569 Country of ref document: EP |